

West London Mental Health NHS Trust Performance in Initiation Q2 2015/16

Research Ethics Committee Reference Number	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Benchmark Met	Comments	Reasons for delay correspond to:
92737/LNW	CIRCLE	06/01/2015	13/01/2015	Yes	30/01/2015	7	17	24	Yes		Unknown
136836/LNW	CBT vs Standardised Medical Care to treat Dissociative Seizures - CODES	23/01/2015	10/02/2015	Yes	09/04/2015	18	58	76	No	This study has a target of 10 recruits over 1114 recruiting days - that's an average of 1 recruit every 111.4 days, as a consequence it seems unreasonable to have a 70 day target for a first recruit.	Neither
151131/LNW	AFFECT Trial	05/01/2015	09/01/2015	No		4			No	this study is difficult to recruit to. We have screened multiple patients for this study and either they are still in screening or have screened failed (for unforeseeable reasons - MMSE changed dramatically from the last time it was conducted, the MRI scan falls out with the criteria etc etc).	NHS Provider
117466/LNW	Minocycline in Alzheimer's Disease Efficacy (MADE) trial	30/12/2014	26/01/2015	Yes	21/05/2015	27	115	142	No	This study is difficult to recruit to. We screened multiple patients within the 70 day period for this trial, but in that period either the screening failed, or they were still being screened.	NHS Provider
157696/LNW	Effective Home Support Dementia Care:Patterns of Current Provision v1	09/04/2015	14/04/2015	No		5			No	Study is difficult to recruit to (hence a target of 1 accrual in 5 months)	Neither

*VRA stands for Valid Research Application

West London NHS Foundation Trust Performance in Delivery Q2 2015/16

Id	Research Ethics Committee Reference Number	Name of Trial	Target number of patients available	Target number of patients	Date Agreed to recruit target number of patients available	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time	Comments
67403	143780/LNW	DeNDRoN 3100 EnVivo EVP-6124-025 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication - EVP-6124-025	Available	12	Available	12/10/2016	Open	Y	Already over-achieved target, still recruiting.